The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution
Open accessAbstract
A remarkable instability at simple repeated sequences characterizes gastrointestinal cancer of the microsatellite mutator phenotype (MMP). Mutations in the DNA mismatch repair gene family underlie the MMP, a landmark for hereditary nonpolyposis colorectal cancer. These tumors define a distinctive pathway for carcinogenesis because they display a particular spectrum of mutated cancer genes containing target repeats for mismatch repair deficiency. One such gene is BAX , a proapoptotic member of the Bcl-2 family of proteins, which plays a key role in programmed cell death. More than half of colon and gastric cancers of the MMP contain BAX frameshifts in a (G) 8 mononucleotide tract. However, the functional significance of these mutations in tumor progression has not been established. Here we show that inactivation of the wild-type BAX allele by de novo frameshift mutations confers a strong advantage during tumor clonal evolution. Tumor subclones with only mutant alleles frequently appeared after inoculation into nude mice of single-cell clones of colon tumor cell lines with normal alleles. In contrast, no clones of BAX-expressing cells were found after inoculation of homozygous cell clones without wild-type BAX . These results support the interpretation that BAX inactivation contributes to tumor progression by providing a survival advantage. In this context, survival analyses show that BAX mutations are indicators of poor prognosis for both colon and gastric cancer of the MMP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Frameshift Mutations and the Genetic Code
Streisinger, G., Okada, Y., Emrich, J., Newton, J., Tsugita, A., Terzaghi, E., & Inouye, M. (1966) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1966.031.01.014 · Cited by 1,400
Bax and Adenine Nucleotide Translocator Cooperate in the Mitochondrial Control of Apoptosis
Marzo, I., Brenner, C., Zamzami, N., Jürgensmeier, J. M., Susin, S. A., Vieira, H. L. A., Prévost, M.-C., Xie, Z., Matsuyama, S., Reed, J. C., et al. (1998) · Science · doi:10.1126/science.281.5385.2027 · Cited by 1,168
Self-citation
Cited by
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
“Furthermore, certain p53 wild-type tumors harbor mutations that can suppress apoptosis downstream of p53 (Meijerink et al., 1998; Ionov et al., 2000; Soengas et al., 2001), and some tumor-derived p53 mutants are defective at inducing apoptosis but not cellcycle arrest (Aurelio et al., 2000).”
Backgroundc-MYC: more than just a matter of life and death
Pelengaris, S., Khan, M., & Evan, G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc904 · Cited by 1,178
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,121
RetractedRole of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Pediatric acute lymphoblastic leukemia
Inaba, H., & Mullighan, C. G. (2020) · Haematologica · doi:10.3324/haematol.2020.247031 · Cited by 696
PUMA mediates the apoptotic response to p53 in colorectal cancer cells
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., & Zhang, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2627984100 · Cited by 563
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Apoptosis-targeted therapies for cancer
Reed, J. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00241-6 · Cited by 500
Self-citationDissecting p53 tumor suppressor functions in vivo
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00047-8 · Cited by 485
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 458
Chemotherapy: targeting the mitochondrial cell death pathway
Debatin, K.-M., Poncet, D., & Kroemer, G. (2002) · Oncogene · doi:10.1038/sj.onc.1206039 · Cited by 396
Bcl2 family proteins in carcinogenesis and the treatment of cancer
Frenzel, A., Grespi, F., Chmelewskij, W., & Villunger, A. (2009) · Apoptosis · doi:10.1007/s10495-008-0300-z · Cited by 331
Apoptosis and genomic instability
Zhivotovsky, B., & Kroemer, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1443 · Cited by 299
Apoptosome dysfunction in human cancer
Hajra, K. M., & Liu, J. R. (2004) · Apoptosis · doi:10.1023/b:appt.0000045786.98031.1d · Cited by 291
Yeager, M. E., Halley, G. R., Golpon, H. A., Voelkel, N. F., & Tuder, R. M. (2001) · Circulation Research · doi:10.1161/01.res.88.1.e2 · Cited by 286
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
Self-citationBonora, M., & Pinton, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00302 · Cited by 208
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Massard, C., Zermati, Y., Pauleau, A.-L., Larochette, N., Métivier, D., Sabatier, L., Kroemer, G., & Soria, J.-C. (2006) · Oncogene · doi:10.1038/sj.onc.1209487 · Cited by 144
Metadata
- Authors
- Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J. C., & Perucho, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-09-12
- Volume
- 97
- Issue
- 20
- Pages
- 10872-10877
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2051136861
- Cited by
- 242
- References
- 4
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.